Loading...
Market
Primary outcome measure in first clinical trial of prime editing approach for CFTR F508del mutation by Dec 31, 2025?
2
Resolution / Starting Odds
Safety • 25%
Efficacy • 25%
Both • 25%
Other • 25%
ClinicalTrials.gov or official trial documentation
Story
New Prime Editing Approach Corrects CFTR F508del Mutation in Human Lung Cells
Jul 10, 2024, 12:02 PM
Scientists have developed a prime editing approach that efficiently corrects the most common cystic fibrosis mutation in human lung cells, which could pave the way to a one-time treatment as effective as existing daily therapies. The systematic application of six recent prime editing developments has enabled the correction of the CFTR F508del mutation in primary airway cells from cystic fibrosis (CF) patients. This research, reported in Nature Biomedical Engineering, suggests the potential for a one-time treatment that addresses the root cause of the disease. While additional work lies ahead, these findings mark a significant step forward in the treatment of cystic fibrosis.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
United Kingdom • 25%
Other • 25%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Pfizer • 25%
Moderna • 25%
Novartis • 25%
Other • 25%
USA • 25%
UK • 25%
Germany • 25%
Other • 25%